Deutsche Bank AG Invests $105.80 Million in United Therapeutics Corporation $UTHR

Key Points

• Deutsche Bank acquired 195,269 shares of United Therapeutics in the second quarter, worth approximately $105.8 million and representing about 0.46% of the company. Institutional investors collectively own 94.08% of UTHR.
• United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $646, while company insiders sold approximately $235.4 million worth of shares over the past 90 days.

Deutsche Bank AG acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 195,269 shares of the biotechnology company's stock, valued at approximately $105,803,000. Deutsche Bank AG owned about 0.46% of United Therapeutics at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Leuthold Group LLC increased its holdings in shares of United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock valued at $5,200,000 after acquiring an additional 3,126 shares during the last quarter. UBS Group AG boosted its position in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock worth $110,045,000 after purchasing an additional 70,445 shares during the period. Nicholas Investment Partners LP boosted its position in United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock worth $2,218,000 after purchasing an additional 3,766 shares during the period. M&T Bank Corp grew its holdings in United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company's stock valued at $1,531,000 after purchasing an additional 1,985 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in United Therapeutics during the fourth quarter valued at approximately $633,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Up 2.1%

Shares of UTHR stock opened at $529.14 on Thursday. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The firm has a market cap of $22.69 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. The stock has a 50 day moving average of $534.23 and a 200-day moving average of $537.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter last year, the company posted $6.41 earnings per share. United Therapeutics's quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $506.59, for a total transaction of $4,812,605.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $164,359,579.37. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 434,275 shares of company stock worth $235,371,678 over the last 90 days. Company insiders own 8.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on UTHR shares. Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Finally, Weiss Ratings upgraded shares of United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source